Good day everyone. Let's now turn to the United States, our most important commercial market and a key driver of long-term growth.
As Nick said, the US launch is on track for Q4 2026, and this is supported by expanding patient identification, increasing experience with tiratricol in early access program, and continued progress on market access readiness, starting with patient identification. We've now identified more than 140 genetically confirmed patients, and that number continues to grow each quarter. Our field medical team is now fully deployed, engaging specialist centers that are central to patient identification and treatment. They're engaging with physicians across endocrinology, neurology, and clinical genetics, with the focus on centers already managing known patients, increasing disease awareness, and enabling meaningful clinical dialogue, and accelerating diagnosis and referral pathways. We're also expanding our presence at key scientific meetings, including the American College of Medical Genetics, which took place in the first quarter, and the Pediatric Endocrine Society, which is taking place this week and is our most important meeting.
These engagements are critical to connecting with healthcare professionals, sharing emerging data, advancing the earlier recognition and diagnosis of MCT8 deficiency. Just as importantly, we continue to build strong relationships with the MCT8 caregiver and advocacy community. This engagement helps us better understand the patient journey, incorporate caregiver perspectives, inform our plans, and strengthen the trust with the families. Our US Early Access program continues to expand.
With 50 patients now receiving treatment across 20 specialist centers. This program enables access for patients with significant unmet need while also providing physicians with real-world experience managing tiratricol.
These insights are helping us inform our implementation approach, deepen engagement with specialist centers, and better define the support that will be required for both patients and providers; over time, we are also making solid progress in building the access and patient support infrastructure that is needed for launch.
Our work has now moved from implementation to execution, with national account directors now engaging Medicaid and commercial payers to communicate the seriousness of the disease, the lack of approved treatment options, and to strengthen our clinical and real-world evidence.
In parallel, we've selected our three 3PL and specialty pharmacy partners, and we're advancing our patient support program, which will include the specialty pharmacy integration, benefit verification, and the patient services to ensure that we have seamless access for both patients and physicians from day one. Finally, we're building the team to deliver on this opportunity.
We're establishing a US organization led by experienced rare disease experts across medical affairs, market access and commercial, with a strong track record in rare disease and first-in-class launches.
Over the past quarter, we've continued to expand these functions to ensure launch readiness, and we remain on track to reach approximately 25 US colleagues at launch. We believe this is the right scale to capture the opportunity while maintaining capital discipline.
So together, this progress is translating into strong launch readiness. We're gaining greater visibility into the patient population, seeing strong engagement from specialists. We're addressing the needs of patients with high unmet medical need, with tiratricol and having constructive early discussions with payers. This supports our confidence in a successful launch at approval and over time, establishing tiratricol as the standard of care with MCT8 Deficiency.
Thanks for your attention, and I'll now turn it over to Henrik for an update on commercialization in Europe.